NCT03979703

Brief Summary

Fibrosing interstitial lung diseases are characterized by loss of lung function, which leads to a decrease in quality of life and physical capacity. Several studies have shown an increase in quality of life and physical capacity after increasing physical activity in patients. There is evicence that yoga has a positive influence in patients with chronic obstructive pulmonary diseases, but so far, studies examining the effect of yoga in patients with fibrosing interstitial lung diseases are missing. Study aims are to determine the feasibilty of this study, and to determine the effects of yoga to patients' quality of life and physical capacity. Twenty patients with a fibrosing interstitial lung disease will be recruited and randomly assigned to the intervention or control group. Several questionnaires regarding quality of life will be conducted. Furthermore, the 6 minutes walking test, a lung function test and a biomarker analysis will be conducted at baseline and follow-up. The intervention group will participate in a 12 week yoga class, whereas the controll group will not participate. Yoga classes will be offered to the control group after the study. In addition, focus group interviews will be conducted at baseline and follow-up with the intervention group.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
17

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Dec 2018

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2018

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

May 14, 2019

Completed
24 days until next milestone

First Posted

Study publicly available on registry

June 7, 2019

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2019

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 31, 2020

Completed
Last Updated

December 7, 2020

Status Verified

December 1, 2020

Enrollment Period

1.1 years

First QC Date

May 14, 2019

Last Update Submit

December 4, 2020

Conditions

Keywords

fibrosing interstitial lung diseaseIdiopathic Pulmonary FibrosisYoga

Outcome Measures

Primary Outcomes (6)

  • Change from baseline quality of life at 12 weeks: King's Brief Interstitial Lung Disease Questionnaire (K-BILD)

    Quality of life will be measured with King's Brief Interstitial Lung Disease Questionnaire (K-BILD). It is a 15-item validated questionnaire assessing health status in patients with an interstitial lung disease. Questions are related to three domains: breathlessness and activities, psychological aspects, and chest symptoms. Each question has 7 possible answers. The questionnaire has a scale from 0 - 100, in which 100 means highest quality of life.

    baseline and 12 week follow-up

  • Change in physical capacity

    Physical capacity will be measured by the 6 miuntes walking test

    baseline and 12 week follow-up

  • Feasibility of a yoga class in patients with fibrosing interstitial lung diseases: focus group interview

    Evaluation of the study by a focus group interview

    12 week follow-up

  • Change from baseline quality of life at 12 weeks: Hospital Anxiety and Depression Scale (HADS)

    Quality of life will be measured with the Hospital Anxiety and Depression Scale (HADS). It is a 14-item questionnaire, 7 items are related to depression and 7 items are related to anxiety. Each question has 4 different answer options, each scored from 0-3. Scores are summed up for each field (depression or anxiety) with 0 points as lowest possibility and 21 scores as highest (0-7 = normal, 8-10 = borderline abnormal, and 11-21 = abnormal).

    baseline and 12 week follow-up

  • Change from baseline quality of life at 12 weeks: Interstitial Lung Disease Anxiety-questionnaire

    Quality of life will be measured with Interstitial Lung Disease Anxiety-questionnaire. This is a 37-item questionnaire with 5 answer possibilities for each question (never, rare, sometimes, often, always). Total scores are a sum of all questions. Lowest score = 0, highest score = 136. The higher the score the better is the patients' quality of life.

    baseline and 12 week follow-up

  • Expectations of study by participants

    Evaluation of the study by a focus group interview

    baseline

Study Arms (2)

Intervention group

EXPERIMENTAL

Intervention will be a 12 week yoga class

Other: 12 week yoga class

Control group

NO INTERVENTION

Control group will not participate in the 12 week yoga class but will participate in Surveys, 6 minute walking test, lung function test, and biomarker analysis. Furthermore, they will be offered a yoga class after the study.

Interventions

Intervention is a 12 week yoga class with classes twice a week. Each yoga class will last about 1 hour. Furthermore, focus group interviews will be conducted after the first and last yoga class.

Intervention group

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • ability to understand study and study procedure
  • diagnosis of fibrosing interstitial lung disease
  • Age: \> 18 years
  • Ability to consent

You may not qualify if:

  • Forced Vital Capacity \< 50%
  • Oxygen therapy
  • diagnosis of pulmonary hypertension
  • participant does not understand the study
  • pulmonary infection within the last 4 weeks
  • acute exacerbation within the last 4 weeks
  • other respiratory decline within the last 4 weeks
  • co-morbidities which make yoga training impossible

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Thoraxklinik-Heidelberg

Heidelberg, 69126, Germany

Location

MeSH Terms

Conditions

Idiopathic Pulmonary Fibrosis

Condition Hierarchy (Ancestors)

Pulmonary FibrosisLung Diseases, InterstitialLung DiseasesRespiratory Tract Diseases

Study Officials

  • Michael Kreuter, Prof.

    Heidelberg University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator, Clinical Professor

Study Record Dates

First Submitted

May 14, 2019

First Posted

June 7, 2019

Study Start

December 1, 2018

Primary Completion

December 31, 2019

Study Completion

May 31, 2020

Last Updated

December 7, 2020

Record last verified: 2020-12

Data Sharing

IPD Sharing
Will not share

Locations